A new study published in JCI Insight led by Richard S. Hotchkiss, MD, suggests that interleukin-7 (IL-7) may help critically ill COVID-19 patients by reducing life-threatening secondary infections.
IL-7 Treatment Shows Promise in Reducing Lethal Secondary Infections in Critically ill COVID-19 Patients






